http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
노동우,백은아,강수균 한국음성과학회 2003 음성과학 Vol.10 No.4
The purposes of this study are; to investigate the swallowing mechanism of stroke patients with different consistencies through the modified barium swallowina:(MBS): and to establish preliminary data on the differences in swallowing durations. 4 different kinds of consistency-water, nectar, pudding, and crackers-were given to 6 stroke patients and their swallowing durations recorded through the fluoroscopy were measured in 1/100 second units. The results show that first swallowing time(FST), the oral preparatory duration(OPD), and the pharyngeal response duration(PRD) were delayed in swallowing thicker consistencies. However, water exhibited delayed oral and pharyngeal phase relative to its consistency and 50% of subjects showed oral loss of water. The relationship between consistencies and swallowing durations and the clinical issues on the stroke population were discussed.
과잉 PbO에 따른 Pb(Mg, Nb)O₃-PbTiO₃계 세라믹스의 압전특성
김규수,백동수,윤광희,이두희,박창엽,윤현상 연세대학교 산업기술연구소 1993 논문집 Vol.25 No.1
In this study, the dielectric, piezoelectric and structual properties of PMN-PT system ceramics were investigated with respect to the variation of PbO addition amount and sintering temperature. The specimen with 1.0wt% PbO addition exhibits relatively good sintering and piezoelectric properties, which has the density with 97.36%, the coupling constant(kp) with the value of 47.44% and the piezoelectric ?? with ?? at sintering temperature 1000℃ respectively.
이민수,김용구,김영훈,연병길,오병훈,윤도준,윤진상,이철,정희연,강병조,김광수,김동언,김명정,김상훈,김희철,나철,노승호,민경준,박기창,박두병,백기청,백인호,손봉기,손진욱,양병환,양창국,우행원,이정호,이종범,이홍식,임기영,전태연,정영조,정영철,정인과,정인원,지익성,채정호,한상익,한선호,한진희,서광윤 大韓神經精神醫學會 1998 신경정신의학 Vol.37 No.1
연구목적 : 본 시험의 목적은 임상시험 시작전에 연구자들을 대상으로 PANSS Workshop을 통하여 PANSS, ESRS에 대한 국내에서의 표준화 작업을 구축하고 새로운 정신병 치료제인 리스페리돈의 효과와 안정성을 재확인하여 리스페리돈 사용에 대한 적정화를 이루는데 있다. 연구방법 : 1996년 4월부터 1996년 9월까지 국내 39개 대학병원 정신과에 입원중인 혹은 증상이 악화되어 입원하는 정신분열병 환자 377명을 대상으로 다시설 개방 연구를 시행하였다. 1주일간의 약물 배설기간을 가진후, 리스페리돈을 8주간 투여하였고, 기준점, 1주, 2주, 4주, 그리고 8주후에 평가되었다. 용량은 제1일에는 리스페리돈 1mg씩 1일 2회, 제2일에는 2mg씩 1일 2회, 제3∼7일에는 3mg씩 1일 2회 투여하였다. 이후 환자의 임상상태에 따라 임의로 증량할 수 있으며, 최대 일일 16mg을 초과하지 않도록 하였다. 추체외로 증상을 조절하기 위한 투약을 허용하였다. 임상증상 및 부작용의 평가는 PANSS(Positive and Negative Syndrome Scale), CGI(Clinical Global Impression) 그리고 ESRS(Extrapyramidal Symptom Rating Scale)을 사용하였다. 연구결과 : 377명중 343명(91%)이 8주간의 연구를 완결하였다. 치료 종결시점인 8주후 PANSS 총점수가 20% 이상 호전된 경우를 약물 반응군으로 정의할때, 약물반응군은 81.3%였다. 리스페리돈에 반응하는 예측인자로는 발병연령, 이전의 입원 횟수, 유병기간이 관련 있었다. 리스페리돈은 1주후부터 PANSS양성, 음성, 및 일반정신병리 점수상에 유의한 호전을 보여 효과가 빨랐다. CGI의 경우도 기준점에 비해 1주후부터 유의한 감소를 나타내었다. ESRS의 경우, 파킨슨 평가점수는 기준점과 비교해 투여 1주, 2주, 4주후 유의하게 증가되었다가 8주후 기준점과 차이가 없었다. Dystonia 평가점수는 1주후만 유의한 증가를 보였으며, dyskinesia 평가점수는 유의한 차이가 없었다. 혈압, 맥박수의 생명징후 및 일반 혈액학 검사, 생화학적 검사, 심전도 검사에서 유의한 변화는 없었다. 결 론 : 이상의 다시설 개방 임상 연구를 통해 리스페리돈은 정신분열병 환자에서 양성증상뿐만 아니라 음성증상 및 전반적인 증상에도 효과적인 것으로 사료된다. 보다 명확한 평가를 위해서는 다른 항정신병약물과의 이중맹검 연구가 필요할 것으로 생각되며, 또한 장기적 치료에 대한 평가도 함께 이루어져야 하겠다. Objective : The purpose of this study was to investigate the efficacy and safety of risperidone in the treatment of Korean schizophrenic patients. Method : This multicenter open study included 377 schizophrenic patients drawn from 39 university hospitals. After a wash-out period of 1 week, the schizophrenic patients were treated with risperidone for 8 weeks and evaluated at 5 points ; at baseline, and 1, 2, 4 and 8 weeks of treatment. The dose was increased from 2mg/day(1mg twice daily) to 6mg/day(3mg twice daily) during the first week and adjusted to a maximum of 16mg/day over the next 7 weeks according to the patient's clinical response. Medication to control extrapyramidal symptoms was permitted. The psychiatric and neurological status of the patients was assessed by PANSS, CGI, and ESRS scales. Results : 343(91%) of 377 patients completed the 8-week trial period. Clinical improvement, as defined by a 20% or more reduction in total PANSS score at end point, was shown by 81.3% of patients. The predictors of response to risperidone were associated older age, shorter duration of illness, fewer previous hospitalization. Risperidone had rapid onset of action ; a significant decrease of the total PANSS and three PANSS factor(positive, negative, general), and CGI was already noticed at the end of first week. For the ESRS, parkinsonism rating scores were significantly increased until week 4 comparing with baseline. Dystonia rating scores were significantly increased until week 1, and dyskinesia rating scores were not significantly changed during the study. Laboratory parameters including vital sign, EKG, hematological, and biochemical values showed no significant changes during the trial. Conclusions : This study suggests that risperidone is generally safe and effective against both the positive and negative symptoms in our group of patients.
Paik, Kyung Hoon,Song, Seng Mi,Ki, Chang Seok,Yu, Han-Wook,Kim, Jung Sim,Min, Ki Hoon,Chang, Soo Hee,Yoo, Eun Jae,Lee, In Jung,Kwan, Eun Kyung,Han, Sun Joo,Jin, Dong-Kyu Wiley Subscription Services, Inc., A Wiley Company 2005 Human mutation Vol.26 No.4
<P>Mucolipidosis types II and III are autosomal recessive inherited diseases caused by a deficiency in the lysosomal enzyme N-acetylglucosamine-1 phosphotransferase (GlcNAc-phosphotransferase), which adds phosphate to function as a recognition marker for the uptake and transport of lysosomal enzymes. We investigated mutations in the GNPTA (MGC4170) gene, which codes for the α/β subunits of phosphotransferase, and in the GNPTAG gene, which codes for its γ subunits in five Korean patients with mucolipidosis type II or IIIA. We identified seven mutations in the GNPTA gene, but none in GNPTAG. The mutations in type II patients included p.Q104X (c.310C>T), p.R1189X (c.3565C>T), p.S1058X (c.3173C>G), p.W894X (c.2681G>A), and p.H1158fsX15 (c.3474_3475delTA), all of which are nonsense or frameshift mutations. However, a splicing site mutation, IVS13+1G>A (c.2715+1G>A) was detected along with a nonsense or a frameshift mutation (p.R1189X or p.E858fsX3 (c.2574_2575delGA)) in two mucolipidosis type IIIA patients. This report shows that mutations in the GNPTA gene coding for the α/β subunits of phosphotransferase, and not mutations in the GNPTAG gene, account for most of the genetic mutations found in Korean patients with mucolipidosis type II or IIIA. Hum Mutat 26(4), 308–314, 2005. © 2005 Wiley-Liss, Inc.</P>
Nonalcoholic Fatty Liver Disease and Progression of Coronary Artery Calcification: A Cohort Study
( Dong Hyun Sinn ),( Danbee Kang ),( Yoosoo Chang ),( Seungho Ryu ),( Seonhye Gu ),( Hyunkyoung Kim ),( Donghyeong Seong ),( Soo Jin Cho ),( Byoung-kee Yi ),( Hyung-doo Park ),( Seung Woon Paik ),( Yo 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Nonalcoholic fatty liver disease (NAFLD), a hepatic manifestationof the metabolic syndrome, was associated with subclinical atherosclerosis atherosclerosisin many crosssectional studies, but the prospective associationbetween NAFLD and the progression of atherosclerosis has not beenevaluated. This study was conducted to evaluate the association betweenNAFLD and the progression of coronary atherosclerosis.Methods: This cohort study included 4,731 adult men and womenwith no history of CVD, liver disease or cancer at baseline who participatedin a repeated regular health screening exam between 2004and 2013. Fatty liver was diagnosed by ultrasound based on standardcriteria, including parenchymal brightness, liver-to-kidney contrast,deep beam attenuation and bright vessel walls. Progression of coronaryartery calcium (CAC) scores was measured using multidetectorCT scanners.Results: The annual rate of CAC progression in participants with andwithout NAFLD were 22% (95% confidence interval 20 - 23%) and17% (16 - 18%), respectively (p<0.001). The multivariable ratio ofprogression rates comparing participants with NAFLD to those withoutNAFLD was 1.04 (1.02 - 1.05; p<0.001). The association betweenNAFLD and CAC progression was similar in most subgroups analyzed,including in participants with CAC 0 and in those with CAC > 0at baseline.Conclusions: In this large cohort study of adult men and womenwith no history of CVD, NAFLD was significantly associated with thedevelopment of CAC independently of cardiovascular and metabolicrisk factors. NAFLD may play a pathophysiologic role in atherosclerosisdevelopment and may be useful to identify subjects with a higherrisk of subclinical disease progression.
Nonalcoholic Fatty Liver Disease and Development of Chronic Kidney Disease: A Cohort Study
( Dong Hyun Sinn ),( Danbee Kang ),( Hye Ryoun Jang ),( Seonhye Gu ),( Soo Jin Cho ),( Seung Woon Paik ),( Seungho Ryu ),( Yoosoo Chang ),( Mariana Lazo ),( Eliseo Guallar ),( Juhee Cho ),( Geum-youn 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Nonalcoholic fatty liver disease (NAFLD) has been associated with chronic kidney disease (CKD), but cohort studies are limited. We investigated the longitudinal association of NAFLD and its severity with the development of CKD. Methods: We performed a retrospective cohort study of 41,430 adult men and women (average age, 48.9 y) without CKD at baseline who underwent repeated health check-up examinations from January 1, 2003, through December 31, 2013. NAFLD status was assessed by ultrasonography, and NAFLD severity was assessed by the NAFLD fibrosis score (NFS). Results: The outcome was an incident CKD, defined as an estimated glomerular filtration rate less than 60 mL/min/1.73 m<sup>2</sup>. During 200,790 person-years of follow-up (median 4.15 years), we identified 691 incident CKD cases. The multivariable-adjusted hazard ratio for CKD comparing participants with and without NAFLD was 1.22 (95% confidence interval [CI], 1.04-1.43). The risk of CKD increased progressively with increased NAFLD severity. The multivariable-adjusted hazard ratios for CKD comparing participants with NFS < -1.455 and those with NFS ≥ -1.455 to participants without NAFLD were 1.09 (0.91-1.32) and 1.58 (1.30-1.92), respectively. The association was consistent across clinically relevant subgroups. Conclusions: In a large cohort of adult men and women without CKD, NAFLD was associated with an increased risk of CKD development. NAFLD may adversely affect renal function and may need careful attention for an increased risk of CKD.